Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Garrido

Showing results (161-170 of 181) with videos related to

Pageof 19
Sort By:
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Journal for Immunotherapy of Cancer|January 22, 2026
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancerDung T Le, Gunnar Folprecht, Anna M Varghese, et al.
Cancer|April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsDavid S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Gastroenterology|January 20, 2024
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal AdenocarcinomaMax M Wattenberg, Sarah Colby, Ignacio Garrido-Laguna, et al.
Cell|May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistanceBen Sang, Ling Feng Ye, Zheng Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Plos Biology|August 4, 2022
Kelp carbon sink potential decreases with warming due to accelerating decompositionKaren Filbee-Dexter, Colette J Feehan, Dan A Smale, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.
Pageof 19

Showing results (161-170 of 181) with videos related to

Sort By:
Pageof 19
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Journal for Immunotherapy of Cancer|January 22, 2026
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancerDung T Le, Gunnar Folprecht, Anna M Varghese, et al.
Cancer|April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsDavid S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Gastroenterology|January 20, 2024
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal AdenocarcinomaMax M Wattenberg, Sarah Colby, Ignacio Garrido-Laguna, et al.
Cell|May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistanceBen Sang, Ling Feng Ye, Zheng Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Plos Biology|August 4, 2022
Kelp carbon sink potential decreases with warming due to accelerating decompositionKaren Filbee-Dexter, Colette J Feehan, Dan A Smale, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.
Pageof 19